Paper8913832
Active vs. passive resistance, dose-response relationships, high dose chemotherapy, and resistance modulation: a hypothesis.
Stewart DJ and 3 others. Invest New Drugs, 1996. Cited by 34 papers, by iCite.
Cite this record
ConductScience Library. Active vs. passive resistance, dose-response relationships, high dose chemotherapy, and resistance modulation: a hypothesis. Papers, record 8913832. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/8913832
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Active vs. passive resistance, dose-response relationships, high dose chemotherapy, and resistance modulation: a hypothesis.
- PubMed
Topics5
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Drug Resistance, Neoplasm | Major topic |
| Dose-Response Relationship, Drug | |
| Drug Administration Schedule | |
| Humans |
Source PubMed
References63
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 1421389 | All-transretinoic acid followed by intensive chemotherapy gives a high complete remission rate and may prolong remissions in newly diagnosed acute promyelocytic leukemia: a pilot study on 26 cases. | Blood | 1992 | https://conductscience.org/library/papers/1421389 | PubMed |
| 2 | 2553992 | Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors. | J Natl Cancer Inst | 1989 | https://conductscience.org/library/papers/2553992 | PubMed |
| 3 | 1672623 | Assessment of P-glycoprotein, glutathione-based detoxifying enzymes and O6-alkylguanine-DNA alkyltransferase as potential indicators of constitutive drug resistance in human colorectal tumors. | Cancer Res | 1991 | https://conductscience.org/library/papers/1672623 | PubMed |
| 4 | 1692761 | Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. | Cancer Res | 1990 | https://conductscience.org/library/papers/1692761 | PubMed |
| 5 | 3409465 | Glutathione S-transferase isoenzymes and glutathione peroxidase activity in normal and tumour samples from human lung. | Carcinogenesis | 1988 | https://conductscience.org/library/papers/3409465 | PubMed |
| 6 | 8452330 | Biological basis for cancer treatment. | Ann Intern Med | 1993 | https://conductscience.org/library/papers/8452330 | PubMed |
| 7 | 1824825 | A role for the interleukin 1 receptor in the synergistic antitumor effects of human interleukin 1 alpha and etoposide against human melanoma cells. | Cancer Res | 1991 | https://conductscience.org/library/papers/1824825 | PubMed |
| 8 | 3677093 | Differential uptake of cis-diamminedichloroplatinum (II) by sensitive and resistant murine L1210 leukemia cells. | Cancer Res | 1987 | https://conductscience.org/library/papers/3677093 | PubMed |
| 9 | 2686531 | Molecular basis of cisplatin resistance in human carcinomas: model systems and patients. | Anticancer Res | 1989 | https://conductscience.org/library/papers/2686531 | PubMed |
| 10 | 2538680 | Neoadjuvant chemotherapy in marginally resectable stage III M0 non-small cell lung cancer: long-term follow-up in 41 patients. | J Surg Oncol | 1989 | https://conductscience.org/library/papers/2538680 | PubMed |
| 11 | 6346495 | Clinical pharmacology of hepatic arterial chemotherapy. | Semin Oncol | 1983 | https://conductscience.org/library/papers/6346495 | PubMed |
| 12 | 8485653 | Mechanisms by which interferon potentiates chemotherapy. | Cancer Invest | 1993 | https://conductscience.org/library/papers/8485653 | PubMed |
| 13 | 1704879 | Chemotherapy for stage IV non-small cell lung cancer. | Hematol Oncol Clin North Am | 1990 | https://conductscience.org/library/papers/1704879 | PubMed |
| 14 | 8099529 | Expression of resistance factors (P-glycoprotein, glutathione S-transferase-pi, and topoisomerase II) and their interrelationship to proto-oncogene products in renal cell carcinomas. | Cancer | 1993 | https://conductscience.org/library/papers/8099529 | PubMed |
| 15 | 8386368 | Isolation of genetic suppressor elements, inducing resistance to topoisomerase II-interactive cytotoxic drugs, from human topoisomerase II cDNA. | Proc Natl Acad Sci U S A | 1993 | https://conductscience.org/library/papers/8386368 | PubMed |
| 16 | 2539902 | Genetic characterization of the multidrug-resistant phenotype of VM-26-resistant human leukemic cells. | Cancer Res | 1989 | https://conductscience.org/library/papers/2539902 | PubMed |
| 17 | 8094414 | Cell survival measurements at low doses using an automated image cytometry device. | Int J Radiat Biol | 1993 | https://conductscience.org/library/papers/8094414 | PubMed |
| 18 | 1292755 | Synergistic antiproliferative effects of the combination of interleukin-1 alpha and doxorubicin against human melanoma cells. | Oncol Res | 1992 | https://conductscience.org/library/papers/1292755 | PubMed |
| 19 | 7306968 | Relative frequency and kinetic properties of transport-defective phenotypes among methotrexate-resistant L1210 clonal cell lines derived in vivo. | Cancer Res | 1981 | https://conductscience.org/library/papers/7306968 | PubMed |
| 20 | 2545337 | Resistance mechanisms in three human small cell lung cancer cell lines established from one patient during clinical follow-up. | Cancer Res | 1989 | https://conductscience.org/library/papers/2545337 | PubMed |
Cited by12
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 34 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41009436 | Transcriptomic and Cytogenetic Analysis of Oxaliplatin-Resistant Colorectal Adenocarcinoma HCT116 Cells to Identify Markers Associated with Platinum Resistance. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/41009436 | PubMed |
| 34431062 | Mechanism of drug resistance in bacteria: efflux pump modulation for designing of new antibiotic enhancers. | Folia Microbiol (Praha) | 2021 | https://conductscience.org/library/papers/34431062 | PubMed |
| 31142791 | Mechanistic Study of TTF-1 Modulation of Cellular Sensitivity to Cisplatin. | Sci Rep | 2019 | https://conductscience.org/library/papers/31142791 | PubMed |
| 29949049 | Targeting glucose transport and the NAD pathway in tumor cells with STF-31: a re-evaluation. | Cell Oncol (Dordr) | 2018 | https://conductscience.org/library/papers/29949049 | PubMed |
| 26966512 | Novel in vitro and mathematical models for the prediction of chemical toxicity. | Toxicol Res (Camb) | 2013 | https://conductscience.org/library/papers/26966512 | PubMed |
| 24401732 | Decitabine impact on the endocytosis regulator RhoA, the folate carriers RFC1 and FOLR1, and the glucose transporter GLUT4 in human tumors. | Clin Epigenetics | 2014 | https://conductscience.org/library/papers/24401732 | PubMed |
| 22891266 | Tissue platinum concentration and tumor response in non-small-cell lung cancer. | J Clin Oncol | 2012 | https://conductscience.org/library/papers/22891266 | PubMed |
| 20881640 | Extensive disease small cell lung cancer dose-response relationships: implications for resistance mechanisms. | J Thorac Oncol | 2010 | https://conductscience.org/library/papers/20881640 | PubMed |
| 20047843 | Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer. | Crit Rev Oncol Hematol | 2010 | https://conductscience.org/library/papers/20047843 | PubMed |
| 18204976 | A phase II study of sequential docetaxel and gemcitabine followed by docetaxel and carboplatin as first-line therapy for non-small cell lung cancer. | Med Oncol | 2008 | https://conductscience.org/library/papers/18204976 | PubMed |
| 9547669 | Multiple resistance modulators combined with carboplatin for resistant malignancies: a pilot study. | Invest New Drugs | 1997 | https://conductscience.org/library/papers/9547669 | PubMed |
| 9120546 | Cranial radiation and concomitant cisplatin and mitomycin-C plus resistance modulators for malignant gliomas. | J Neurooncol | 1997 | https://conductscience.org/library/papers/9120546 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| ABCB1 | 5243 | PubTator's text mining | https://conductscience.org/library/genes/5243 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/8913832
GET https://conductscience.org/api/papers/v1/8913832/references?page=2